Pharvaris N.V.

NasdaqGS PHVS

Pharvaris N.V. Return on Equity (ROE) for the year ending December 31, 2023: -26.27%

Pharvaris N.V. Return on Equity (ROE) is -26.27% for the year ending December 31, 2023, a 48.64% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Pharvaris N.V. Return on Equity (ROE) for the year ending December 31, 2022 was -51.14%, a -145.29% change year over year.
Pharvaris N.V. Return on Equity (ROE) for the year ending December 31, 2021 was -20.85%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NasdaqGS: PHVS

Pharvaris N.V.

CEO	Mr. Berndt Axel Edvard Modig CPA, M.B.A.
IPO Date	Feb. 5, 2021
Location	Netherlands
Headquarters	J.H. Oortweg 21
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Key trends

Past 5 years